Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2002 Nov;61(Suppl 2):ii43–ii45. doi: 10.1136/ard.61.suppl_2.ii43

Treatments no longer in development for rheumatoid arthritis

E Keystone
PMCID: PMC1766723  PMID: 12379620

Full Text

The Full Text of this article is available as a PDF (67.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carteron N. L., Schimenti C. L., Wofsy D. Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion. J Immunol. 1989 Mar 1;142(5):1470–1475. [PubMed] [Google Scholar]
  2. Choy E. H., Pitzalis C., Cauli A., Bijl J. A., Schantz A., Woody J., Kingsley G. H., Panayi G. S. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum. 1996 Jan;39(1):52–56. doi: 10.1002/art.1780390107. [DOI] [PubMed] [Google Scholar]
  3. Connolly K., Roubinian J. R., Wofsy D. Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity. J Immunol. 1992 Nov 1;149(9):3083–3088. [PubMed] [Google Scholar]
  4. Epstein W. V. Expectation bias in rheumatoid arthritis clinical trials. The anti-CD4 monoclonal antibody experience. Arthritis Rheum. 1996 Nov;39(11):1773–1780. doi: 10.1002/art.1780391102. [DOI] [PubMed] [Google Scholar]
  5. Goldschmidt T. J., Andersson M., Malmström V., Holmdahl R. Activated type II collagen reactive T cells are not eliminated by in vivo anti-CD4 treatment. Implications for therapeutic approaches on autoimmune arthritis. Immunobiology. 1992 Apr;184(4-5):359–371. doi: 10.1016/S0171-2985(11)80593-0. [DOI] [PubMed] [Google Scholar]
  6. Hamidou M. A., Gires C., Moreau A., Martin S., Buzelin F., Grolleau J. Y. Lambda light chain deposition disease presenting as sicca syndrome. Arthritis Rheum. 1997 Mar;40(3):587–588. doi: 10.1002/art.1780400330. [DOI] [PubMed] [Google Scholar]
  7. Lewis E. J., Bishop J., Bottomley K. M., Bradshaw D., Brewster M., Broadhurst M. J., Brown P. A., Budd J. M., Elliott L., Greenham A. K. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol. 1997 Jun;121(3):540–546. doi: 10.1038/sj.bjp.0701150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mason Ursula, Aldrich Jose, Breedveld Ferdinand, Davis Charles B., Elliott Michael, Jackson Mildred, Jorgensen Christian, Keystone Edward, Levy Robert, Tesser John. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol. 2002 Feb;29(2):220–229. [PubMed] [Google Scholar]
  9. Matteson E. L., Yocum D. E., St Clair E. W., Achkar A. A., Thakor M. S., Jacobs M. R., Hays A. E., Heitman C. K., Johnston J. M. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum. 1995 Sep;38(9):1187–1193. doi: 10.1002/art.1780380903. [DOI] [PubMed] [Google Scholar]
  10. Moreland L. W., Pratt P. W., Mayes M. D., Postlethwaite A., Weisman M. H., Schnitzer T., Lightfoot R., Calabrese L., Zelinger D. J., Woody J. N. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum. 1995 Nov;38(11):1581–1588. doi: 10.1002/art.1780381109. [DOI] [PubMed] [Google Scholar]
  11. Olsen N. J., Brooks R. H., Cush J. J., Lipsky P. E., St Clair E. W., Matteson E. L., Gold K. N., Cannon G. W., Jackson C. G., McCune W. J. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum. 1996 Jul;39(7):1102–1108. doi: 10.1002/art.1780390705. [DOI] [PubMed] [Google Scholar]
  12. Olsen N. J., Teal G. P., Strand V. In vivo T cell depletion in rheumatoid arthritis is associated with increased in vitro IgM-rheumatoid factor synthesis. Clin Immunol Immunopathol. 1993 May;67(2):124–129. doi: 10.1006/clin.1993.1054. [DOI] [PubMed] [Google Scholar]
  13. Rasmussen H. S., McCann P. P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75(1):69–75. doi: 10.1016/s0163-7258(97)00023-5. [DOI] [PubMed] [Google Scholar]
  14. Ruderman E. M., Weinblatt M. E., Thurmond L. M., Pinkus G. S., Gravallese E. M. Synovial tissue response to treatment with Campath-1H. Arthritis Rheum. 1995 Feb;38(2):254–258. doi: 10.1002/art.1780380215. [DOI] [PubMed] [Google Scholar]
  15. Tak P. P., van der Lubbe P. A., Cauli A., Daha M. R., Smeets T. J., Kluin P. M., Meinders A. E., Yanni G., Panayi G. S., Breedveld F. C. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum. 1995 Oct;38(10):1457–1465. doi: 10.1002/art.1780381012. [DOI] [PubMed] [Google Scholar]
  16. van Roon J. A., Lafeber F. P., Bijlsma J. W. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum. 2001 Jan;44(1):3–12. doi: 10.1002/1529-0131(200101)44:1<3::AID-ANR2>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  17. van der Lubbe P. A., Dijkmans B. A., Markusse H. M., Nässander U., Breedveld F. C. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum. 1995 Aug;38(8):1097–1106. doi: 10.1002/art.1780380812. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES